Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.
The Company’s patented microinjection dosage form is the only non-surgical method for focal administration of drugs to the retina and choroid through the suprachoroidal space (SCS). Clearside Biomedical has initiated clinical development of its lead product in macular edema following non-infectious uveitis and following retinal vein occlusion, expanded its internal drug development efforts in steroid-sparing anti-inflammatory drugs as well as multikinase inhibitors for wet AMD and is developing additional therapies through collaborations with third parties.
Milestones that have been achieved:
In January 2012, Clearside announced $4 million Series A financing from Hatteras Venture Partners, a venture capital firm based in Research Triangle Park, N.C. Hatteras Venture Partners focuses on seed- and early-stage prospects in biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. The financing funded the development of Clearside Biomedical’s ocular microinjection platform, the initial clinical testing of the company’s lead product for inflammation and the establishment of Clearside Biomedical’s team of scientific experts in offices in Alpharetta and Raleigh.
The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With four funds, the firm has more than $200 million under management.
The microinjection platform was developed cooperatively by the laboratories of Mark Prausnitz, Ph.D., Regents’ Professor and Love Family Professor of Chemical & Biomolecular Engineering at the Georgia Institute of Technology, and Henry Edelhauser, Ph.D., Emeritus Professor in the Department of Ophthalmology at Emory University School of Medicine.
The research was supported by the National Eye Institute, which is part of the National Institutes of Health, and by the organization Research to Prevent Blindness.
The researchers’ study was reported in the July, 2012 issue of Investigative Ophthalmology & Visual Science. In addition to demonstrating that microneedles can deliver drug molecules and particles to the eye, the study established that the suprachoroidal space could accommodate a variety of drugs and microparticles.